PL3424953T3 - Lecznicze przeciwciała - Google Patents
Lecznicze przeciwciałaInfo
- Publication number
- PL3424953T3 PL3424953T3 PL18175085T PL18175085T PL3424953T3 PL 3424953 T3 PL3424953 T3 PL 3424953T3 PL 18175085 T PL18175085 T PL 18175085T PL 18175085 T PL18175085 T PL 18175085T PL 3424953 T3 PL3424953 T3 PL 3424953T3
- Authority
- PL
- Poland
- Prior art keywords
- therapeutic antibodies
- antibodies
- therapeutic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168787 | 2011-06-06 | ||
| US201161505137P | 2011-07-07 | 2011-07-07 | |
| EP12159172 | 2012-03-13 | ||
| PCT/EP2012/060524 WO2012168199A1 (en) | 2011-06-06 | 2012-06-04 | Therapeutic antibodies |
| EP12725447.2A EP2718322B1 (en) | 2011-06-06 | 2012-06-04 | Therapeutic antibodies |
| EP18175085.2A EP3424953B1 (en) | 2011-06-06 | 2012-06-04 | Therapeutic antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3424953T3 true PL3424953T3 (pl) | 2021-01-25 |
Family
ID=47295509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18175085T PL3424953T3 (pl) | 2011-06-06 | 2012-06-04 | Lecznicze przeciwciała |
| PL12725447T PL2718322T3 (pl) | 2011-06-06 | 2012-06-04 | Lecznicze przeciwciała |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12725447T PL2718322T3 (pl) | 2011-06-06 | 2012-06-04 | Lecznicze przeciwciała |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US8613926B2 (OSRAM) |
| EP (3) | EP3798230B1 (OSRAM) |
| JP (2) | JP6141834B2 (OSRAM) |
| KR (1) | KR101978757B1 (OSRAM) |
| CN (1) | CN103596982B (OSRAM) |
| AU (1) | AU2012266487B2 (OSRAM) |
| BR (1) | BR112013031198B1 (OSRAM) |
| CA (1) | CA2838497C (OSRAM) |
| DK (3) | DK2718322T3 (OSRAM) |
| ES (2) | ES2929575T3 (OSRAM) |
| IL (1) | IL229254A (OSRAM) |
| PL (2) | PL3424953T3 (OSRAM) |
| PT (1) | PT3424953T (OSRAM) |
| RU (1) | RU2616881C2 (OSRAM) |
| TW (1) | TWI564305B (OSRAM) |
| WO (1) | WO2012168199A1 (OSRAM) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2616881C2 (ru) * | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| SG11201601844TA (en) * | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| WO2015140591A1 (en) * | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| CA2955788C (en) | 2014-07-22 | 2024-01-16 | Ziyong Sun | Anti-pd-1 antibodies |
| US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| US20170328898A1 (en) * | 2014-10-31 | 2017-11-16 | Cell Trend GmbH | Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor |
| BR112018009129A2 (pt) * | 2015-11-04 | 2019-02-26 | J. PRICEMAN Saul | receptores de antígeno quimérico que visam her2 |
| CA3005986A1 (en) * | 2015-11-23 | 2017-06-01 | Innate Pharma | Cd39 vascular isoform targeting agents |
| HUE064791T2 (hu) | 2015-11-25 | 2024-04-28 | Visterra Inc | APRIL ellenes antitest molekulák és alkalmazásaik |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| AR107505A1 (es) | 2016-01-22 | 2018-05-09 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulación xi |
| WO2017218371A1 (en) | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| AU2017313085B2 (en) | 2016-08-19 | 2024-06-20 | Beone Medicines I Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| TWI774726B (zh) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途 |
| MX2019010848A (es) | 2017-03-16 | 2019-10-30 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| KR20240149979A (ko) * | 2017-05-25 | 2024-10-15 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 중쇄 불변 영역을 포함하는 항체 |
| TWI877099B (zh) | 2017-06-26 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 |
| WO2019034580A1 (en) * | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| WO2019092148A1 (en) * | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| JP7500442B2 (ja) | 2018-06-18 | 2024-06-17 | イナート・ファルマ・ソシエテ・アノニム | 癌を処置するための組成物及び方法 |
| JP7654548B2 (ja) | 2018-09-17 | 2025-04-01 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 抗ｋｌｒｇ１抗体 |
| US20220041719A1 (en) * | 2018-12-05 | 2022-02-10 | Morphosys Ag | Multispecific antigen-binding molecules |
| BR112021017860A2 (pt) * | 2019-03-14 | 2021-12-07 | Morphosys Ag | Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica |
| US20230220042A1 (en) * | 2019-12-03 | 2023-07-13 | Shanghai Jiao Tong University School Of Medicine | Antibody fc region having enhanced binding affinity to fcyriib |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| GB2595299B (en) * | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| JP2023537417A (ja) | 2020-08-12 | 2023-08-31 | イナート・ファルマ・ソシエテ・アノニム | アブドラリマブによる皮下抗Ｃ５ａＲアンタゴニスト治療レジメン |
| US20230374147A1 (en) | 2020-11-02 | 2023-11-23 | Hummingbird Bioscience Pte. Ltd. | Bcma/taci antigen-binding molecules |
| US11912781B2 (en) | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| US20240150484A1 (en) | 2021-03-12 | 2024-05-09 | Genmab A/S | Non-activating antibody variants |
| US20250313631A1 (en) | 2021-09-16 | 2025-10-09 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| WO2023046979A1 (en) | 2021-09-27 | 2023-03-30 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| AU2022361691A1 (en) * | 2021-10-08 | 2024-03-28 | Genmab A/S | Antibodies binding to cd30 and cd3 |
| WO2023109928A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海宝济药业有限公司 | 抗免疫球蛋白降解酶酶切的Fc变体 |
| CN120092020A (zh) | 2022-07-08 | 2025-06-03 | 新加坡科技研究局 | Cnx抗原结合分子 |
| CA3265385A1 (en) | 2022-08-22 | 2024-02-29 | Abdera Therapeutics Inc. | DLL3 BINDING MOLECULES AND THEIR USES |
| WO2024062073A1 (en) | 2022-09-22 | 2024-03-28 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| AU2024206166A1 (en) | 2023-01-03 | 2025-06-12 | Hummingbird Bioscience Pte. Ltd. | Her3-binding antibody-drug conjugate |
| CN121002069A (zh) | 2023-01-06 | 2025-11-21 | 泰温治疗私人有限公司 | 抗原结合分子 |
| EP4646439A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| WO2025125495A1 (en) | 2023-12-13 | 2025-06-19 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| WO2025133322A1 (en) | 2023-12-22 | 2025-06-26 | Agency For Science, Technology And Research | Cnx antigen-binding molecules |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
| WO2025257350A1 (en) | 2024-06-13 | 2025-12-18 | Singapore Health Services Pte Ltd | Pai-1 antigen-binding molecules |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JPH02262599A (ja) | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製Ｃ５ａレセプター |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| US5844094A (en) | 1992-09-25 | 1998-12-01 | Commonwealth Scientific And Industrial Research Organization | Target binding polypeptide |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5480974A (en) | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US20010036650A1 (en) | 1994-08-16 | 2001-11-01 | Human Genome Sciences, Inc. | C5a receptor |
| US5861272A (en) | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
| JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗Ｃ５ａレセプター抗体、その製造法および用途 |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| WO1996039511A2 (en) | 1995-06-05 | 1996-12-12 | Incyte Pharmaceuticals, Inc. | A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| WO1998033908A1 (en) | 1997-01-31 | 1998-08-06 | Incyte Pharmaceuticals, Inc. | Human c5a-like receptor |
| JP2002505574A (ja) | 1997-04-30 | 2002-02-19 | エンゾン，インコーポレイテッド | ポリアルキレンオキシド修飾された単鎖ポリペプチド |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| WO2002038767A2 (en) | 2000-11-07 | 2002-05-16 | Genetics Institute, Llc. | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI334439B (en) * | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| ATE453661T1 (de) | 2001-09-27 | 2010-01-15 | Merck & Co Inc | Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| ES2646792T3 (es) | 2002-01-25 | 2017-12-18 | Novo Nordisk A/S | Anticuerpos monoclonales contra bucles extracelulares de C5aR |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| JP2006513702A (ja) | 2002-09-09 | 2006-04-27 | ヌラ インコーポレーティッド | Ｇタンパク質共役受容体およびその使用 |
| AU2002952086A0 (en) | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| WO2004082568A2 (en) | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| EP1586583A3 (en) | 2004-04-16 | 2005-11-16 | Alligator Bioscience AB (publ) | Compounds that block C5a complement receptor and their use in therapy |
| MX2007011064A (es) * | 2005-03-23 | 2008-02-19 | Genmab As | Anticuerpos contra cd38 para tratamiento de mieloma multiple. |
| WO2007055374A1 (ja) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
| KR20090053899A (ko) * | 2006-08-22 | 2009-05-28 | 지투 인플레메이션 피티와이 엘티디 | 개선된 특성을 갖는 항-ｃ５ａｒ 항체 |
| EP2061812A4 (en) | 2006-08-22 | 2010-06-09 | G2 Inflammation Pty Ltd | METHOD FOR THE PRODUCTION OF ANTIBODIES |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| WO2009053368A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
| RU2010138612A (ru) | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
| WO2009149081A1 (en) | 2008-06-02 | 2009-12-10 | Novelmed Therapeutics, Inc. | Method for treating inflammatory conditions |
| US20090324585A1 (en) | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
| WO2010000864A1 (en) | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| WO2011100477A2 (en) | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| EP3216462A3 (en) | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
| KR20130086144A (ko) | 2010-05-28 | 2013-07-31 | 노보 노르디스크 에이/에스 | 항체 및 보존제를 포함하는 안정한 다중-투여 조성물 |
| EP2588499B1 (en) * | 2010-06-30 | 2020-04-08 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| JP2013532176A (ja) * | 2010-07-15 | 2013-08-15 | ノヴォ ノルディスク アー／エス | 安定化させた第ｖｉｉｉ因子バリアント |
| WO2012088247A2 (en) * | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Anti-c5/c5a/c5adesr antibodies and fragments |
| RU2616881C2 (ru) * | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
| WO2014180961A1 (en) | 2013-05-08 | 2014-11-13 | Novo Nordisk A/S | Use of c5ar antagonists |
-
2012
- 2012-06-04 RU RU2013155029A patent/RU2616881C2/ru active
- 2012-06-04 BR BR112013031198-3A patent/BR112013031198B1/pt active IP Right Grant
- 2012-06-04 ES ES20187662T patent/ES2929575T3/es active Active
- 2012-06-04 ES ES12725447.2T patent/ES2693647T3/es active Active
- 2012-06-04 CN CN201280028064.1A patent/CN103596982B/zh active Active
- 2012-06-04 PL PL18175085T patent/PL3424953T3/pl unknown
- 2012-06-04 EP EP20187662.0A patent/EP3798230B1/en active Active
- 2012-06-04 DK DK12725447.2T patent/DK2718322T3/en active
- 2012-06-04 DK DK18175085.2T patent/DK3424953T3/da active
- 2012-06-04 EP EP18175085.2A patent/EP3424953B1/en active Active
- 2012-06-04 DK DK20187662.0T patent/DK3798230T3/da active
- 2012-06-04 PL PL12725447T patent/PL2718322T3/pl unknown
- 2012-06-04 KR KR1020137034239A patent/KR101978757B1/ko active Active
- 2012-06-04 WO PCT/EP2012/060524 patent/WO2012168199A1/en not_active Ceased
- 2012-06-04 EP EP12725447.2A patent/EP2718322B1/en active Active
- 2012-06-04 PT PT181750852T patent/PT3424953T/pt unknown
- 2012-06-04 CA CA2838497A patent/CA2838497C/en active Active
- 2012-06-04 AU AU2012266487A patent/AU2012266487B2/en not_active Ceased
- 2012-06-04 JP JP2014514023A patent/JP6141834B2/ja active Active
- 2012-06-06 TW TW101120198A patent/TWI564305B/zh active
- 2012-06-06 US US13/490,093 patent/US8613926B2/en active Active
-
2013
- 2013-06-18 US US13/920,585 patent/US8846045B2/en active Active
- 2013-11-05 IL IL229254A patent/IL229254A/en active IP Right Grant
-
2014
- 2014-08-25 US US14/467,393 patent/US20150044231A1/en not_active Abandoned
-
2016
- 2016-11-02 US US15/341,550 patent/US10323097B2/en active Active
- 2016-12-07 JP JP2016237458A patent/JP6416177B2/ja active Active
-
2019
- 2019-06-17 US US16/443,736 patent/US10882916B2/en active Active
-
2020
- 2020-12-18 US US17/127,688 patent/US20210238300A1/en not_active Abandoned
-
2023
- 2023-12-11 US US18/536,032 patent/US20240218076A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL229254A0 (en) | Therapeutic antibodies | |
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| IL221288A0 (en) | Therapeutic methods using anti-cd200 antibodies | |
| ZA201307983B (en) | Anti-b7-h3 antibody | |
| IL239339A0 (en) | Therapeutic 47cd antibodies | |
| IL231604B (en) | Therapeutic peptides | |
| IL230719A0 (en) | highly galactosylated antibodies | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201119401D0 (en) | Therapeutic agents | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| ZA201502595B (en) | Therapeutic methods | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201102913D0 (en) | Novel therapeutic | |
| ZA201308992B (en) | Therapeutic antibodies | |
| GB201120096D0 (en) | Novel therapy | |
| GB201116342D0 (en) | Antigen combinations | |
| GB201115558D0 (en) | Therapeutic agents | |
| GB201101128D0 (en) | Therapeutic agents | |
| GB201110614D0 (en) | Therapeutic agents | |
| GB201110895D0 (en) | Therapeutic use |